NASDAQ · Biotechnology · USD
Clearmind Medicine Inc. (CMND) Stock Analysis
Clearmind Medicine Inc. (CMND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CMND Key Statistics
As of Oct 21, 2026Trading
- Open
- $6.25
- Previous Close
- $6.12
- Day's Range
- 5.94–6.25
- 52-Week Range
- 5.25–3,840.00
- Volume
- 5.22K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.46
Valuation
- Market Cap
- $3.19M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −461.20
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$3.86M
- Shares Outstanding
- 507.40K
- 1-Year Return
- −98.56%
Dividend and dates
- Avg Volume
- 63.17K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CMND closed at $5.94, −98.56% over 1 year.
Clearmind Medicine Inc. (CMND) has a market capitalization of $3.19M.
In fiscal 2025, CMND reported revenue of $0.00.
CMND Stock Return by Calendar Year
Clearmind Medicine Inc. (CMND) return since Nov 2022: what $10,000 became
- 1 year
- $10,000 $144
- −98.56%
- 3 years
- $10,000 $34
- −99.66%
- Since Nov 2022
- $10,000 $0.84
- −99.99%
If you had invested $10,000 in Clearmind Medicine Inc. (CMND) at the close on November 15, 2022, the earliest close on record here, it would have been worth $0.84 at the close on October 21, 2026: −99.99% in total, −90.81% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −67.18% |
| 2025 | −96.72% |
| 2024 | −50.89% |
| 2023 | −97.04% |
| 2022 (partial year) | −46.44% |
As of October 21, 2026.
CMND Revenue and Earnings by Fiscal Year
FY ends October| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$3.86M | — |
| 2024 | $0.00 | −$5.25M | — |
| 2023 | $0.00 | −$8.62M | — |
| 2022 | $0.00 | −$6.89M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$5.67M | −$3.86M | — |
| 2024 | $0.00 | — | −$5.74M | −$5.25M | — |
| 2023 | $0.00 | — | −$6.30M | −$8.62M | — |
| 2022 | $0.00 | — | −$6.25M | −$6.89M | — |
Annual figures as reported, in the company's reporting currency. As of October 31, 2025.
Recent News
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
YahooClearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform
BenzingaClearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
YahooClearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia
BenzingaClearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
YahooClearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
Benzinga
All 20 articles ↓Show fewer ↑
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
YahooSciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
YahooClearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
YahooClearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide
BenzingaClearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
YahooClearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
YahooClearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
YahooClearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100
BenzingaClearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million
InvestorsHubClearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
YahooClearmind Medicine Stock Slides Friday: What's Happening?
BenzingaClearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
YahooClearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
BenzingaSciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B